Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis

Company Overview

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Key Stats

• Today's Range: $47.50 to $47.50
• 50-Day Range: $47.50 to $54.00
• 52-Week Range: $47.50 to $54.00
• Volume: N/A
• Average Volume: 55 shs
• Market Capitalization: $625.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

BPMUF Stock Analysis - Frequently Asked Questions

How have BPMUF shares performed this year?

Basilea Pharmaceutica's stock was trading at $52.83 at the start of the year. Since then, BPMUF stock has decreased by 10.1% and is now trading at $47.50.
View the best growth stocks for 2025 here.

Does Basilea Pharmaceutica have any subsidiaries?

Basilea Pharmaceutica subsidiaries include Conec UK Limited.

How do I buy shares of Basilea Pharmaceutica?

Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/31/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:BPMUF
• CIK: N/A
• Web: www.basilea.com
• Phone: (161) 606-1111
• Fax: 41-61-606-1112
• Employees: 147
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 5.70
• Current Ratio: 4.10
• Quick Ratio: 3.27

Sales & Book Value

• Annual Sales: $175.50 million
• Price / Sales: 3.56
• Cash Flow: $1.02 per share
• Price / Cash Flow: 46.75
• Book Value: ($0.94) per share
• Price / Book: -50.53

Miscellaneous

• Outstanding Shares: 13,170,000
• Free Float: N/A
• Market Cap: $625.58 million
• Optionable: Not Optionable
• Beta: 0.47